Research & Development World

  • R&D World Home
  • Topics
    • Aerospace
    • Automotive
    • Biotech
    • Careers
    • Chemistry
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Software
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
    • Semiconductors
  • R&D Market Pulse
  • R&D 100
    • Call for Nominations: The 2025 R&D 100 Awards
    • R&D 100 Awards Event
    • R&D 100 Submissions
    • Winner Archive
    • Explore the 2024 R&D 100 award winners and finalists
  • Resources
    • Research Reports
    • Digital Issues
    • Educational Assets
    • R&D Index
    • Subscribe
    • Video
    • Webinars
  • Global Funding Forecast
  • Top Labs
  • Advertise
  • SUBSCRIBE

How is R&D helping the fight against COVID-19?

By Heather Hall | March 10, 2020

With the outbreak of the COVID-19 virus sending panic around the globe it may well seem as if the world is on the back foot in our fight against it.

However, R&D tax credit specialists, RIFT Research and Development Ltd., has looked at how R&D is helping in the fight against it, not only as a result of current investment, but learnings from previous outbreaks over the last decade in particular.

In the last 10 years, there have been as many as 10 pandemic or epidemic outbreaks with notable death tolls, ranging from the Flu pandemic (influenza) in 2009 to multiple cholera and measles outbreaks, Ebola, swine flu and the current Coronavirus.

While the Coronavirus is a cause of concern at present, HIV/Aids (36.2%), Tuberculosis (17.7%) and the main strain of Malaria (9.3%) remain the diseases receiving the largest sums of R&D investment when it comes to the fight against them.

However, the Coronavirus is just the third disease seen in the last decade to spread on a global scale and will no doubt see a huge sum invested in R&D, although thankfully it remains near the bottom of the table where the death toll is concerned.

How is R&D helping to combat it to keep the death toll low?

Reactive measures are the largest area of R&D investment in relation to epidemic or pandemic risk diseases with vaccines to treat these emerging threats seeing the largest degree of R&D investment in the last 10 years. £9,088,000 ($11,815,790.46) to be exact, accounting for a notable 34.7% of all investment in the area.

However, work is always ongoing and the basic research around these diseases has seen the second largest proportion of investment (22.1%), while drugs to treat those infected have seen the third largest level of investment at 21%.

But it isn’t just treatment and medicine that R&D enables. In 2000, the Global Outbreak Alert and Response Unit was founded, a technical collaboration of institutions that pools resources via a range of networks when responding to outbreaks of international importance.

The same year GAVI the vaccine alliance was also founded which greatly improved access to vaccines and immunization.

In 2005, the International Health Regulation formed an international law to prevent, control and respond to disease, while in 2013 an alliance called GloPID-R was formed which brings together funding organizations to enable research within just 48 hours of a major outbreak showing pandemic potential.

Other disease specific R&D frameworks have also been formed in that time but perhaps the most significant was the creation of the R&D Blueprint in 2016. This delivered a global strategy and preparedness plan designed to facilitate the rapid mobilization of all R&D disease prevention activities during an outbreak. Its role is to fast track effective tests, vaccines, and medicines in order to fight an outbreak as soon as possible, saving lives, stopping the spread and preventing a major crisis.

When it comes to the spread of Coronavirus, residents of the UK can rest a little easier than most. The UK has seen the second-largest percentage of total funding in the fight against neglected diseases in the last decade (8.8%) – second only to the U.S.

Director of RIFT Research and Development, Sarah Collins commented:

“An unknown and rapid outbreak of disease like the Coronavirus is a real cause for worry and at ground level, we should all take the necessary precautions to do our bit in the fight against it.

However, thanks to previous R&D learnings and investment into vaccines, research and medicines, we are in a far better place to tackle this outbreak than we might otherwise have been 10 years ago.

While R&D investment on the frontline fight is essential, the infrastructure we now have in place to deliver these vaccines, medication and knowledge on a global scale means we can reduce the number of those affected dramatically and at least slow the pace of the outbreak until it is under control.

As with all areas of R&D this isn’t a temporary focus and the fight against pandemic disease outbreaks will continue, although we hope its application in a real-world scenario remains a rarity.”

For more information go to riftresearch.com

Recent pandemics/epidemics by largest estimated death toll (2009-2019)
Year/period Information Location Estimated death toll
2008–2009 Cholera Zimbabwe 4,293
2009 Flu pandemic (influenza) Worldwide 203,000
2010–present Cholera Hispaniola/Haiti 9,985 (May 2017)
2011–present Measles The Democratic Republic of the Congo > 4,500 (February 2014)
2013–2016 Ebola virus Worldwide – primarily West Africa > 11,300
2015 Swine flu India 2,035
2016–present Cholera Yemen 3,886 (November 2019)
August 2018–present Kivu Ebola epidemic Democratic Republic of the Congo and Uganda 2,253 (February 2020)
2019–present Measles Democratic Republic of the Congo 5,000 (November 2019)
2019–present Coronavirus Worldwide 4,000 (March 2020)
Top 10 R&D investments by disease (2009-2018)
By disease type R&D Investment (£ millions) % of total
HIV / AIDS 9,479 36.2%
Tuberculosis 4,645 17.7%
P. falciparum – the main type of malaria 2,437 9.3%
Multiple/other malaria strains 1,747 6.7%
Core funding of multi-disease / neglected diseases 1,173 4.5%
Dengue 639 2.4%
S. pneumoniae 541 2.1%
P. vivax 466 1.8%
Other neglected disease R&D 459 1.8%
Rotavirus 425 1.6%
Other 4,167 15.9%
TOTAL 26,179 100.0%
Source: Welcome: Advancing R&D to keep up with a changing world
Top 10 investments by type of R&D in relation to epidemic risk diseases (2009-2019)
Type of R&D R&D Investment (£ millions) % of total
Vaccines 9,088 34.7%
Basic Research 5,774 22.1%
Drugs 5,496 21.0%
Unspecified 2,514 9.6%
Microbicides 1,358 5.2%
Diagnostics 1,147 4.4%
Chemical vector control products 241 0.9%
Biological vector control products 189 0.7%
Adjuvants and immunomodulators 108 0.4%
General diagnostic platforms 106 0.4%
Other 158 0.6%
TOTAL 26,179 100.0%
Source: Welcome: Advancing R&D to keep up with a changing world

 

Sources: Welcome: Advancing R&D to keep up with a changing world
World Health Organization: Prioritizing diseases for research and development in emergency contexts

Source: Policy Cure Research

Comments

  1. William Tucker says

    March 12, 2020 at 2:55 pm

    Good Job, thoughtful, mature planning structures. Thank you for your diligence.

Related Articles Read More >

For the first time, scientists grow beating human-pig hearts for 21 days
Open-source Boltz-2 can speed binding-affinity predictions 1,000-fold
Thermo Fisher’s new Orbitrap Excedion Pro targets complex biotherapeutics for drug development
FDA’s new ‘Elsa’ AI set to expedite clinical protocol reviews
rd newsletter
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest info on technologies, trends, and strategies in Research & Development.
RD 25 Power Index

R&D World Digital Issues

Fall 2024 issue

Browse the most current issue of R&D World and back issues in an easy to use high quality format. Clip, share and download with the leading R&D magazine today.

Research & Development World
  • Subscribe to R&D World Magazine
  • Enews Sign Up
  • Contact Us
  • About Us
  • Drug Discovery & Development
  • Pharmaceutical Processing
  • Global Funding Forecast

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search R&D World

  • R&D World Home
  • Topics
    • Aerospace
    • Automotive
    • Biotech
    • Careers
    • Chemistry
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Software
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
    • Semiconductors
  • R&D Market Pulse
  • R&D 100
    • Call for Nominations: The 2025 R&D 100 Awards
    • R&D 100 Awards Event
    • R&D 100 Submissions
    • Winner Archive
    • Explore the 2024 R&D 100 award winners and finalists
  • Resources
    • Research Reports
    • Digital Issues
    • Educational Assets
    • R&D Index
    • Subscribe
    • Video
    • Webinars
  • Global Funding Forecast
  • Top Labs
  • Advertise
  • SUBSCRIBE